PD-1 (21-35) PG-W-FLDSPDRP-W-NPP-amide

  • Description

  • Application Data

Description

PD-1 (21-35) peptide is derived from the programmed cell death-1 (PD-1) which interacts with its ligand, PD-L1 to regulate immune homeostasis.

See full description

Application Data

Catalogue number crb1000338
Molecular Weight 1778.9
Sequence (one letter code) PG-W-FLDSPDRP-W-NPP-amide
Sequence (three letter code) H-Pro-Gly-Trp-Phe-Leu-Asp-Ser-Pro-Asp-Arg-Pro-Trp-Asn-Pro-Pro-NH2
Molecular Weight 1778.9
Purity >95%
References

Shen and Zhao (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362 k3529 doi:https://doi.org/10.1136/bmj.k3529

Francisco et al (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236 219 PMID 20636820.

Fife and Pauken (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. New York Acad. Sci. 1217 45 PMID 21276005

Data Sheet Material Safety Data Sheet (MSDS)

PD-1 (21-35) peptide is derived from the programmed cell death-1 (PD-1) which interacts with its ligand, PD-L1 to regulate immune homeostasis. PD-1 and its ligand PD-L1 are critical in regulating T cell activation, tolerance and immuno-pathology. PD-1 is an immune checkpoint and guards against autoimmunity through two mechanisms. First, it promotes apoptosis of antigen-specific T-cells in lymph nodes. Second, it reduces apoptosis in regulatory T cells.

Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immuno-surveillance mechanism. Consequently PD-1 inhibitors and PD-L1 inhibitors could be used as a therapeutic in the treatment of cancers.

PD-1 (21-35)

Cat No.Pack SizePriceQty.
1mg£110.00
0.5mg£85.00
Bulk Quote